Study Evaluating Venlafaxine ER in Adults With Panic Disorder
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00038896
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|